Trial · NCT03703297
Results by group20
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 20
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Durvalumab Versus Placebo: Progression-Free Survival (PFS) Assessed by Blinded Independent Central Review (BICR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 | Durvalumab | 16.6 | 95% Confidence Interval 10.2 to 28.2 | months | |
| Durvalumab Versus Placebo: Progression-Free Survival (PFS) Assessed by Blinded Independent Central Review (BICR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 | Placebo | 9.2 | 95% Confidence Interval 7.4 to 12.9 | months | |
| Durvalumab Versus Placebo: Overall Survival (OS) | Durvalumab | 55.9 | 95% Confidence Interval 37.3 to NA | months | |
| Durvalumab Versus Placebo: Overall Survival (OS) | Placebo | 33.4 | 95% Confidence Interval 25.5 to 39.9 | months | |
| Durvalumab Versus Placebo: Objective Response Rate (ORR) Assessed by Blinded Independent Central Review Per Response Evaluation Criteria in Solid Tumors Version 1.1 | Durvalumab | 30.3 | percentage of participants | ||
| Durvalumab Versus Placebo: Objective Response Rate (ORR) Assessed by Blinded Independent Central Review Per Response Evaluation Criteria in Solid Tumors Version 1.1 | Placebo | 32.0 | percentage of participants | ||
Durvalumab Versus Placebo: Percentage of Participants Progression-Free at 18 Months Following Randomization (PFS18) Assessed by Blinded Independent Central Review Per Response Evaluation Criteria in Solid Tumors Version 1.1 | Durvalumab | 48.8 | 95% Confidence Interval 42.2 to 55.0 | percentage of participants | |
Durvalumab Versus Placebo: Percentage of Participants Progression-Free at 18 Months Following Randomization (PFS18) Assessed by Blinded Independent Central Review Per Response Evaluation Criteria in Solid Tumors Version 1.1 | Placebo | 36.1 | 95% Confidence Interval 29.9 to 42.2 | percentage of participants | |
Durvalumab Versus Placebo: Percentage of Participants Progression-Free at 24 Months Following Randomization (PFS24) Assessed by Blinded Independent Central Review Per Response Evaluation Criteria in Solid Tumors Version 1.1 | Durvalumab | 46.2 | 95% Confidence Interval 39.6 to 52.5 | percentage of participants | |
Durvalumab Versus Placebo: Percentage of Participants Progression-Free at 24 Months Following Randomization (PFS24) Assessed by Blinded Independent Central Review Per Response Evaluation Criteria in Solid Tumors Version 1.1 | Placebo | 34.2 | 95% Confidence Interval 28.2 to 40.3 | percentage of participants | |
| Durvalumab Versus Placebo: Percentage of Participants Alive at 24 Months From Randomization (OS24) | Durvalumab | 68.0 | 95% Confidence Interval 61.9 to 73.3 | percentage of participants | |
| Durvalumab Versus Placebo: Percentage of Participants Alive at 24 Months From Randomization (OS24) | Placebo | 58.5 | 95% Confidence Interval 52.3 to 64.3 | percentage of participants | |
| Durvalumab Versus Placebo: Percentage of Participants Alive at 36 Months From Randomization (OS36) | Durvalumab | 56.5 | 95% Confidence Interval 50.0 to 62.5 | percentage of participants | |
| Durvalumab Versus Placebo: Percentage of Participants Alive at 36 Months From Randomization (OS36) | Placebo | 47.6 | 95% Confidence Interval 41.3 to 53.7 | percentage of participants | |
| Durvalumab: Serum Concentration of Durvalumab | Durvalumab | Cycle 1 Day 1: End of infusion | 431.00 | Standard Deviation 327.861 | microgram per milliliter (mcg/mL) |
| Durvalumab: Serum Concentration of Durvalumab | Durvalumab | Cycle 2 (Week 4): Pre-infusion | 89.57 | Standard Deviation 107.228 | microgram per milliliter (mcg/mL) |
| Durvalumab: Serum Concentration of Durvalumab | Durvalumab | Cycle 5 (Week 16): Pre-infusion | 159.63 | Standard Deviation 58.561 | microgram per milliliter (mcg/mL) |
| Durvalumab: Serum Concentration of Durvalumab | Durvalumab | Cycle 26 (Week 100): Pre-infusion | 178.20 | Standard Deviation 65.422 | microgram per milliliter (mcg/mL) |
| Durvalumab: Serum Concentration of Durvalumab | Durvalumab | Month 3 follow-up | 44.97 | Standard Deviation 36.026 | microgram per milliliter (mcg/mL) |
| Durvalumab: Number of Participants With Anti-Drug Antibody (ADA) Response to Durvalumab | Durvalumab | 7 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03703297/results